Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146962 | 0.74 | NCF1 (0.47) | GPR3KDM4EMAOAALDH1A1GLA | |
| SCHEMBL411657 | 0.74 | CYP1A2 (0.45) | GPR3KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1826639 | 0.74 | MAOA (0.41) | GPR3KDM4EMAOAALDH1A1GLA | |
| SCHEMBL9479290 | 0.74 | CYP1A2 (0.38) | GPR3KDM4EMAOAALDH1A1GLA | |
| SCHEMBL442600 | 0.74 | IDO1 (0.39) | GPR3KDM4EMAOAALDH1A1GLA | |
| SCHEMBL4461176 | 0.74 | GPR3 (0.37) | GPR3KDM4EMAOAALDH1A1GLA | |
| SCHEMBL2116932 | 0.72 | NOS1 (0.34) | — | |
| SCHEMBL5751117 | 0.71 | TNKS2 (0.40) | GPR3KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4073308 | 0.69 | KDM1A (0.40) | GPR3KDM4EMAOAALDH1A1GLA | |
| SCHEMBL2300258 | 0.69 | BACE1 (0.36) | GPR3KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291345-B1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6924276-B2 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | CHEN MICHAEL HUAI GU (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | SORENSON RODERICK JOSEPH (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | AADAC, AHR, AADAT | GPR3 3299/4885KDM4E 861/4885MAOA 38/4885 |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP3, MMP9 | GPR3 111/4885KDM4E 1800/4885MAOA 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.